Key result
Stable COPD is linked to moderately elevated NT-proBNP levels versus healthy controls.
Why the study?
The study aimed to evaluate variations in NT-proBNP levels across distinct patient groups with COPD, which is frequently associated with cardiovascular comorbidities.
Does COPD and its various disease stages increase NT-proBNP levels in adult patients?
Meta-Analysis (n=8,534)
Does COPD and its various disease stages increase NT-proBNP levels in adult patients?
Standardized Mean Difference: 0.51 (95% CI 0.13–0.89)
p-value: p=0.0092
NT-proBNP levels are significantly elevated in COPD and fluctuate with disease severity, acute exacerbations, and cardiovascular complications, indicating its potential value as a biomarker in respiratory disease.
Elevated NT-proBNP in stable COPD may reflect cardiac involvement; supports biomarker research but leaves clinical utility open.
Purpose: NT-proBNP, a peptide biomarker synthesized and secreted by cardiomyocytes in response to cardiac load, has gained attention in recent years for its potential role in respiratory diseases. Chronic Obstructive Pulmonary Disease (COPD), a chronic and progressive inflammatory condition affecting the respiratory system, is frequently associated with comorbidities involving the cardiovascular system. Consequently, the aim of this systematic review and meta-analysis was to evaluate the variations in NT-proBNP levels across distinct patient groups with COPD and establish a foundation for future investigations into the precise clinical significance of NT-proBNP in COPD. Methods: The search databases for this study were conducted in PubMed, Excerpt Medica database (Embase), Web of Science (WOS), and Cochrane Library databases. Databases were searched for studies on the predictive value of NT-proBNP in adult COPD patients. Results: A total of 29 studies (8534 participants) were included. Patients with stable COPD exhibit elevated levels of NT-proBNP [standardized mean difference(SMD) [95CI%]=0.51 [0.13,0.89]; p =0.0092]. COPD patients with predicted forced expiratory volume in 1 s (FEV 1 ) < 50% exhibit significantly elevated levels of NT-proBNP compared to those with FEV 1 ⩾50%[SMD [95CI%]=0.17 [0.05,0.29]; p =0.0058]. NT-proBNP levels were significantly higher in acute exacerbations (AECOPD) compared to patients with stable COPD [SMD [95CI%]=1.18 [0.07,2.29]; p =0.037]. NT-proBNP levels was significantly higher in non-survivors than in survivors of hospitalised AECOPD patients [SMD [95CI%]=1.67 [0.47,2.88]; p =0.0063]. Both COPD patients with pulmonary hypertension(PH) [SMD [95CI%]=0.82 [0.69,0.96]; p < 0.0001] and chronic heart failure(CHF) [SMD [95CI%]=1.49 [0.96,2.01]; p < 0.0001] showed higher NT-proBNP level. Conclusion: NT-proBNP, a biomarker commonly used in clinical practice to evaluate cardiovascular disease, demonstrates significant variations in different stages of COPD and during the progression of the disease. The fluctuations in NT-proBNP levels could be indicative of the severity of pulmonary hypoxia and inflammation and cardiovascular stress among COPD patients. Therefore, assessing NT-proBNP levels in COPD patients can aid in making informed clinical decisions.
No takes yet. Share an insight, caveat, or question.
Su et al. (2023) conducted a meta-analysis in Chronic Obstructive Pulmonary Disease (COPD) (n=8,534). COPD vs. Healthy controls was evaluated on NT-proBNP levels (SMD 0.51, 95% CI 0.13-0.89, p=0.0092). Stable COPD patients exhibited significantly elevated levels of NT-proBNP compared to healthy controls (SMD 0.51, p=0.0092).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: